Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine

Anne Derbise (1) , Chloé Guillas (1) , Christiane Gerke (2) , Elisabeth Carniel (1) , Javier Pizarro-Cerdá (1) , Christian E. Demeure (1)

1 Yersinia
2 SAI - Développement de l'Innovation - Service des Accords Industriels

A single oral inoculation to mice of the live attenuated Yersinia pseudotuberculosis VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 108 CFU induced dose-dependent antibody production. At the dose of 107 CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of Yersinia pestis. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations.

Keywords: Yersinia pseudotuberculosis; Yersinia pestis; Subcutaneous; Bubonic plague; Live vaccine; Pneumonic plague

Domains: Vaccinology; Innate immunity; Adaptive immunology; Allergology; Bacteriology; Infectious diseases

Anne Derbise, Chloé Guillas, Christiane Gerke, Elisabeth Carniel, Javier Pizarro-Cerdá, et al.. Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine. Vaccine, 2020, 38 (8), pp.1888-1892. ⟨10.1016/j.vaccine.2020.01.014⟩. ⟨pasteur-02493687⟩